Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 22;21(21):7820. doi: 10.3390/ijms21217820

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Antibody-based therapeutic strategies to improve neutrophil-mediated anticancer immune responses. (A) panel 1. Whereas IgA outperforms IgG in terms of neutrophil activation, IgGs are the optimal isotype to activate natural killer (NK) cells. Therefore, a combination of both isotypes would be needed to activate all types of immune cells. (A) panel 2. CD89-activating IgG-based bispecifics have been designed, which activate neutrophils as well as NK cells. Furthermore, the IgG backbone overcomes various problems of IgA antibodies, such as the reduced serum half-life of IgA. (B) panel 1. The interaction of cancer cell expressed CD47 with signal-regulatory protein alpha (SIRPα) expressed on neutrophils inhibits antibody antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), and trogocytosis, even in the presence of activating IgG/IgA antibodies. (B) panel 2. CD47 blocking antibodies have been designed to “release the break” on the activation of phagocytes.